Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corp (NQ: ADPT )

4.370 -0.050 (-1.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corp

< Previous 1 2 3 4 5 6 Next >
Adaptive Announces Launch of Epic Integration for clonoSEQ®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. 
Via InvestorPlace
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
A Preview Of Adaptive Biotechnologies's Earnings
Via Benzinga
Adaptive Biotechnologies's Return On Capital Employed Insights
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite stocks. 
Via The Motley Fool
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M
Via Benzinga
Topics Earnings
Exposures Financial
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead
Via Benzinga
Cathie Wood's Ark Invest Continues To Sell Shopify Shares Amid Q2 Ripples
Via Benzinga
Adaptive Biotechnologies: Q1 Earnings Insights
Via Benzinga
Cathie Wood's Ark Invest Sells More Tesla Stock — Acquires Shares Of Flying Taxi Company
Via Benzinga
Cathie Wood's Ark Invest Sells $2.15M Of Tesla Shares Despite Own Bullish Projections
Via Benzinga
Cathie Wood's Ark Invest Acquires $5.5M of Robinhood Shares Following Platform's First Profitable Quarter
Via Benzinga
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Trump Advisor Says Ex-President May Skip Initial Republican Presidential Primary Debates
Via Benzinga
Cathie Wood's Ark Pours $3.3M More Into This Chipmaker Amid AI Frenzy: Here Are Other Major Monday Trades
Via Benzinga
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
Why Shares of Adaptive Biotechnologies Jumped This Week
The company could see its first FDA-approved therapy as early as next year. 
Via The Motley Fool
Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought
There are always stocks to buy if you're Ark Invest's ace stock picker. 
Via The Motley Fool
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
There are always stocks to buy if you're Ark Invest's ace stock picker. 
Via The Motley Fool
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out. 
Via InvestorPlace
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platform 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.